M

Molecure SA
WSE:MOC

Watchlist Manager
Molecure SA
WSE:MOC
Watchlist
Price: 10.3 PLN -1.15% Market Closed
Market Cap: 173.4m PLN
Have any thoughts about
Molecure SA?
Write Note

Intrinsic Value

The intrinsic value of one MOC stock under the Base Case scenario is 21.76 PLN. Compared to the current market price of 10.3 PLN, Molecure SA is Undervalued by 53%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MOC Intrinsic Value
21.76 PLN
Undervaluation 53%
Intrinsic Value
Price
M
Worst Case
Base Case
Best Case

Valuation Backtest
Molecure SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for MOC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about MOC?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Molecure SA

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Molecure SA

Provide an overview of the primary business activities
of Molecure SA.

What unique competitive advantages
does Molecure SA hold over its rivals?

What risks and challenges
does Molecure SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Molecure SA.

Provide P/S
for Molecure SA.

Provide P/E
for Molecure SA.

Provide P/OCF
for Molecure SA.

Provide P/FCFE
for Molecure SA.

Provide P/B
for Molecure SA.

Provide EV/S
for Molecure SA.

Provide EV/GP
for Molecure SA.

Provide EV/EBITDA
for Molecure SA.

Provide EV/EBIT
for Molecure SA.

Provide EV/OCF
for Molecure SA.

Provide EV/FCFF
for Molecure SA.

Provide EV/IC
for Molecure SA.

Show me price targets
for Molecure SA made by professional analysts.

What are the Revenue projections
for Molecure SA?

How accurate were the past Revenue estimates
for Molecure SA?

What are the Net Income projections
for Molecure SA?

How accurate were the past Net Income estimates
for Molecure SA?

What are the EPS projections
for Molecure SA?

How accurate were the past EPS estimates
for Molecure SA?

What are the EBIT projections
for Molecure SA?

How accurate were the past EBIT estimates
for Molecure SA?

Compare the revenue forecasts
for Molecure SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Molecure SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Molecure SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Molecure SA compared to its peers.

Compare the P/E ratios
of Molecure SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Molecure SA with its peers.

Analyze the financial leverage
of Molecure SA compared to its main competitors.

Show all profitability ratios
for Molecure SA.

Provide ROE
for Molecure SA.

Provide ROA
for Molecure SA.

Provide ROIC
for Molecure SA.

Provide ROCE
for Molecure SA.

Provide Gross Margin
for Molecure SA.

Provide Operating Margin
for Molecure SA.

Provide Net Margin
for Molecure SA.

Provide FCF Margin
for Molecure SA.

Show all solvency ratios
for Molecure SA.

Provide D/E Ratio
for Molecure SA.

Provide D/A Ratio
for Molecure SA.

Provide Interest Coverage Ratio
for Molecure SA.

Provide Altman Z-Score Ratio
for Molecure SA.

Provide Quick Ratio
for Molecure SA.

Provide Current Ratio
for Molecure SA.

Provide Cash Ratio
for Molecure SA.

What is the historical Revenue growth
over the last 5 years for Molecure SA?

What is the historical Net Income growth
over the last 5 years for Molecure SA?

What is the current Free Cash Flow
of Molecure SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Molecure SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Molecure SA

Current Assets 54.5m
Cash & Short-Term Investments 52.4m
Receivables 637.4k
Other Current Assets 1.5m
Non-Current Assets 54.3m
PP&E 9.9m
Intangibles 44.4m
Current Liabilities 9.4m
Accounts Payable 6.7m
Accrued Liabilities 536.5k
Other Current Liabilities 2.2m
Non-Current Liabilities 5.3m
Long-Term Debt 5m
Other Non-Current Liabilities 302.5k
Efficiency

Earnings Waterfall
Molecure SA

Revenue
360.2k PLN
Cost of Revenue
-2m PLN
Gross Profit
-1.6m PLN
Operating Expenses
-23.3m PLN
Operating Income
-24.9m PLN
Other Expenses
3m PLN
Net Income
-21.9m PLN

Free Cash Flow Analysis
Molecure SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

MOC Profitability Score
Profitability Due Diligence

Molecure SA's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Negative 1-Year Revenue Growth
Negative Operating Income
Negative Net Income
19/100
Profitability
Score

Molecure SA's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

MOC Solvency Score
Solvency Due Diligence

Molecure SA's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
87/100
Solvency
Score

Molecure SA's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MOC Price Targets Summary
Molecure SA

Wall Street analysts forecast MOC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MOC is 23.72 PLN with a low forecast of 16.67 PLN and a high forecast of 31.5 PLN.

Lowest
Price Target
16.67 PLN
62% Upside
Average
Price Target
23.72 PLN
130% Upside
Highest
Price Target
31.5 PLN
206% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for MOC?

Click here to dive deeper.

Dividends

Molecure SA
does not pay dividends
Shareholder Yield

Current shareholder yield for MOC is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Molecure SA

Country

Poland

Industry

Pharmaceuticals

Market Cap

173.4m PLN

Dividend Yield

0%

Description

Molecure SA engages in the discovery and development of small molecules for the treatment of unmet medical needs. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 106 full-time employees. The company went IPO on 2018-04-19. The firm is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The firm's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The firm has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.

Contact

WOJ. MAZOWIECKIE
Warsaw
Zwirki i Wigury 101
+48225526724
molecure.com

IPO

2018-04-19

Employees

106

Officers

Co-Founder, CEO & President of Management Board
Dr. Marcin Jan Szumowski Ph.D.
CFO & Member of the Management Board
Mr. Slawomir Piotr Broniarek
Chief Scientific Officer & Member of Management Board
Dr. Zbigniew Zaslona
Member of Management Board & HR Director
Ms. Agnieszka Rajczuk-Szczepanska
Co-Founder & VP of Research Chemistry
Dr. Adam Golebiowski Ph.D.
Co-Founder & Head of Medicinal Chemistry
Mr. Jacek Olczak Ph.D.
Show More
Chief Medical Officer & Member of Management Board
Dr. Piotr Iwanowski
Head of CMC
Ms. Magdalena Tyszkiewicz
Director of the Management Board Office
Ms. Marta Borkowska
Show Less

See Also

Discover More
What is the Intrinsic Value of one MOC stock?

The intrinsic value of one MOC stock under the Base Case scenario is 21.76 PLN.

Is MOC stock undervalued or overvalued?

Compared to the current market price of 10.3 PLN, Molecure SA is Undervalued by 53%.

Back to Top